971.1500 7.55 (0.78%)
NSE Apr 02, 2026 15:31 PM
Volume: 212.2K
 

971.15
0.78%
Geojit BNP Paribas
The company reiterated its $400mn revenue target for FY28, supported by over 60 pending low-competition U.S. launches, while management remains constructive on other regulated markets, where an expanding product portfolio and new customer additions are expected to drive stronger growth and eventually scale these markets to revenue levels comparable with the U.S. business....
Geojit BNP Paribas upgraded Strides Pharma Science Ltd. to Buy with a price target of 1119.0 on 27 Mar, 2026.
More from Strides Pharma Science Ltd.
Recommended